Skip to main content
. Author manuscript; available in PMC: 2014 Jan 6.
Published in final edited form as: Cancer. 2011 Oct 17;118(11):10.1002/cncr.26577. doi: 10.1002/cncr.26577

Table 3.

Front-line chemotherapy regimens used, median number of cycles, serious adverse effects

Protocol Responders (N=17) Non-Responders (N=35) Cycles Total (N=52)
CyVADic 9 10 Median=6 19
CyADic 3 9 Median=5.5 12
CyVDic 5 5 Median=9 10
CyAV 0 2 Median=1.5 2
CyA 0 1 1 1
CHOP 0 1 2 1
Imatinib 0 1 1 1
Cis + VP16 0 1 3 1
AVDic 0 1 6 1
Cy + V + temozolomide 0 1 12 1
Carb + VP16 + ifosfamide 0 1 4 1
Tamoxifen 0 1 4 1
Temozolomide + bevacizumab + sorafenib 0 1 4 1

Cy indicates cyclophosphamide; V, vincristine; A, doxorubicin; Dic, dacarbazine; Cis, cisplatin; VP-16, etoposide; Carb, carboplatin; CHOP, cyclophosphamide, doxorubicin, vincristine and prednisone

N= number of patients.